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Approximately two million people develop deep-vein thrombosis (DVT) annually, and of these an estimated 200 000 die from a fatal pulmonary embolism (PE). [1] Fifty percent of these cases are 'silent' , and the first sign or symptom of venous thromboembolic disease (VTED) is a fatal PE. [2] VTED accounts for 10% of all hospital deaths, [3] and approximately 1 in 20 hospitalised medical patients may develop a fatal PE if they have not received appropriate thrombosis prophylaxis. [4] If not fatal, untreated venous thromboembolism (VTE) may have serious consequences such as risk of recurrent VTE, [1] postthrombotic syndrome, [1] chronic thromboembolic pulmonary hypertension [5] and reduced quality of life. [6] The prevalence of VTE and the use of pharmacological thromboprophylaxis in total hip replacement (THR), total knee replacement (TKR) and hip fractures have been well documented in published literature and in clinical trials. [1, [7] [8] [9] [10] Although there is potentially an increased risk of VTE in foot and ankle surgery, the incidence of VTE is poorly understood. None of the available studies are comparable owing to non-uniformity of the patient populations, failure to distinguish between symptomatic and silent thrombosis, the considerable diversity in foot and ankle pathology, and varying aftercare protocols, which may be why the reported incidence of VTE after foot and ankle surgery ranges widely, from 0% to 36%. A database study in the National Health Service in the UK found that the rate of symptomatic VTED following ankle fracture surgery, total ankle replacement, hindfoot arthrodesis or first metatarsal surgery was <0.3% for each type of surgery. [34] Mizel et al. [21] found prevalences of symptomatic DVT and non-fatal PE of 0.22% and 0.15%, respectively.
In a prospective study using colour duplex Doppler ultrasonography, we found a 1% incidence of DVT in 100 patients following hallux surgery. [35] Lapidus et al., [36] however, found a 28% DVT rate in patients after ankle fracture surgery who did not receive pharmacological prophylaxis. In two studies following Achilles tendon rupture repair, the incidences of DVT were 36% [19] and 6%. [26] In a more recent prospective study, we found an 8.5% incidence of VTE in patients who required immobilisation in a below-knee cast and non-weightbearing for ≥4 weeks after foot and ankle surgery. [37] Two patients developed a PE. Neither of them had shown any clinical evidence of DVT.
Although the majority of recent studies do not advocate the routine use of chemoprophylaxis in foot and ankle surgery, [6, 12, 13, 21, 22, 25, 27, 30, 33, [38] [39] [40] several authors recommend its use in patients with identifiable specific clinical risk factors. [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 26, 37, 41] A difficulty of long-term follow-up of patients is that many DVT events occur several weeks or longer after discharge. [37, 42] 
In the case of post-thrombotic syndrome, which may affect 20 -50% of patients diagnosed with DVT, most symptoms become apparent within 2 years of developing DVT. [43] VTE is essentially a disease with short-term mortality and long-term morbidity.
Objective
To determine whether prophylactic chemoprophylaxis had any impact on the prevention of VTE in a cohort of foot and ankle surgical patients requiring the combination of below-knee cast immobilisation and nonweightbearing for ≥4 weeks, identified by us as a risk factor for VTE in a previous study, [37] and therefore whether its routine administration is justified in these selected patients.
The primary outcome measure was the development of clinical VTE, including infrapopliteal DVT, proximal DVT and PE. Proximal DVT and PE are the potentially fatal conditions, but infrapopliteal DVT may have serious consequences, as outlined above.
At the time of the study, two direct oral anticoagulants were readily available. Rivaroxaban (Xarelto; Bayer) was chosen arbitrarily.
Methods
All patients aged >18 years who underwent foot and ankle surgery requiring the combination of below-knee immobilisation in a cast and non-weightbearing for ≥4 weeks were included in this prospective study. Patients who were already on anticoagulants or had previously had a DVT were excluded. During the period March 2014 -April 2015, 142 consecutive patients who met the criteria were identified. No patient refused to participate.
After giving informed consent, every patient included in the study received rivaroxaban 10 mg orally for 4 -6 weeks, i.e. until he or she no longer required nonweightbearing or cast immobilisation (whichever one came first). The first dose was given at 06h00 on the first day postoperatively, and the drug was administered 24-hourly thereafter.
Before the operation, all patients completed a thrombosis risk assessment form ( Fig. 1) , adapted from Caprini [41] and en dorsed by the Southern African Society of Thrombosis and Haemostasis. The higher the score, the higher is the risk of developing a DVT. Tourniquet time, procedure groups and smoking were included as possible risk factors. The above risk factors were identified so that the present study would be comparable with our previous study, [37] in which no patient had received any ven ous thromboprophylaxis postoperatively.
The primary outcome measure was the development of a clinically evident DVT, as confirmed by compression ultrasonography or a ventilation/perfusion lung scan in the case of PE.
Ethics approval was obtained from the Human Research Ethics Committee (Medical) of the University of the Wit watersrand, Johannesburg (ref. no. M131165).
Results
There were 75 male and 67 female patients, with a mean age of 50.9 years (range 20 -78). Table 1 summarises the procedure groups. The average body mass index (BMI) (kg/m 2 ) was 29 (range 18 -55) and the average risk factor score was 7 (range 3 -15). Fourteen patients (9.9%) were smokers or had smoked within 1 year prior to surgery. Average tourniquet time was 86 minutes (range 33 -150).
Three patients (2.1%) developed a clinically evident DVT, confirmed by compression ultrasonography. Two were extensive (proximal to the calf). One patient developed a clinical DVT 5 weeks after an acute Achilles tendon rupture repair. He admitted being non-compliant in taking his anticoagulation, which had been prescribed for 4 weeks. The other two patients (triple fusion and ankle arthrodesis) developed a DVT at 9 weeks and 14 weeks, respectively, well after completion of the prophylactic anticoagulant, which had been prescribed for 6 weeks.
Five patients (3.5%) developed wound breakdown and were referred to a plastic surgeon. Two required major debridement (internal fixatives were not removed) and closure with a local skin flap. The remaining three were treated with appropriate dressings.
One patient developed menorrhagia, which may have been related to the anticoagulant. The drug was stopped until the menorrhagia abated, and then resumed.
Two patients stopped taking their anticoagulant a few days after surgery because they suspected that there was bleeding under the cast. When the cast was removed no active bleeding was noted, and the drug was resumed within 2 weeks following surgery.
One of the three patients who developed a DVT was a smoker. The average risk factor score in these three patients was 7 (range 6 -8) v. 7.7 (range 4 -13) in the VTE group in our previous study, [37] in which the average BMI was 34 (range 32 -36) . The average tourniquet time in the previous study was 92 minutes (range 55 -120). The numbers were too small for statistical analysis. None of the above three patients developed a clinically evident DVT while they were receiving the anticoagulant. 
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Discussion
Little has been written on the development and prophylaxis of VTE in foot and ankle surgery. Individual patient-and procedure-specific risk factors have been implicated in the development of VTE. [37] The more universally accepted risk factors have been adopted by Caprini [41] and are widely used worldwide. The concern about using anticoagulation is possible adverse events. These have been thoroughly investigated in clinical trials using TKR, THR and hip fracture models, with figures of 2.9 -6.5% for nonmajor bleeding, 0.6 -1.0% for wound-related infections, <0.1 -4.9% for major bleeding, 0 -0.4% for cerebrovascular adverse events, and 0 -1.4% for death from any cause. [7] [8] [9] [10] The decision whether or not to use thrombosis chemoprophylaxis is therefore decided by weighing up the patient's risk for bleeding against the risk of developing VTE. No universal guidelines are available, although the general consensus from various bodies [31, 34, 38, 40] and published articles [6, 12, 13, 21, 22, 24, 25, 27, 30, 33, 39] is that use of prophylactic anticoagulation is not advocated in foot and ankle surgery In a previous prospective study, [37] we found that the absolute number of cases of VTE after foot and ankle surgery was unacceptably high (11/130 (8.5%)), although this was not statistically significant owing to the relatively small number of cases. We identified a cohort of patients who were particularly prone to developing VTE after foot and ankle surgery. They did not have individual or procedure-specific risk factors per se, but were a group requiring the combination of cast immobilisation and non-weightbearing for a period of ≥4 weeks. Using the χ 2 test with a level of significance of p<0.05, the present study demonstrated that the incidence of DVT (2.1%) decreased significantly from 8.5% [37] (p=0.01) when prophylactic anticoagulation was given.
It is also important to note that one of the three patients who developed a DVT was non-compliant, and the other two developed a DVT several weeks after completion of the prophylactic anticoagulation.
Adverse events possibly caused by the anticoagulant were superficial wound sepsis (3.5%) and menorrhagia (0.7%). Procedures in the patients who developed superficial sepsis requiring a skin graft in theatre were a triple fusion, mid-tarsal fusion and non-union of the tibia, with an average risk factor score of 7 (range 6 -8). There were no smokers in this group.
We appreciate the disadvantage of rivaroxaban as a potential cause of bleeding, particularly in emergency 'second-look' surgery. However, such an emergency rarely occurs in foot and ankle surgery, and in the infrequent case when a second-look procedure is required in a patient receiving rivaroxaban 10 mg/d, a waiting period of 8 hours will suffice. If more urgent intervention is needed, a readily available procoagulant can be administered.
Rivaroxaban 10 mg film-coated tablets are indicated for the prevention of VTE in patients undergoing major orthopaedic surgery of the lower limbs. Although all the clinical trials have been limited to TKR, THR and hip fracture surgery, we considered that the same regimen would be adequate and safe in patients undergoing foot and ankle surgery where anticoagulation was indicated. Furthermore, the choice of using this mode of prophylaxis over the standard low-molecular-weight (LMW) heparin injection was the ease of administration and the cost factor (a 40 mg LMW heparin injection is approximately three times the price of 10 mg rivaroxaban as a once-daily dose).
Study limitations are the relatively small number of patients, the lack of routine postoperative duplex Doppler studies (therefore missing silent DVTs), and the absence of a concurrent study as control.
Conclusions
The current study was initiated 2 years after conclusion of the previous study by the same senior surgeons. The methodology, demographics, mode of anaesthesia and risk factors were comparable. On the basis of the previous study, we consider that a group of patients has been identified who will probably benefit from receiving prophylactic anticoagulation in foot and ankle surgery. We noted a significant decrease in the risk of developing VTE in patients requiring a combination of cast immobilisation and non-weightbearing status for a period of ≥4 weeks who received rivaroxaban.
We found that the risk/benefit ratio favours the administration of prophylactic anticoagulation, as the adverse events of such medication are relatively minor compared with life-threatening PE, and in the case of non-fatal VTED, the expense of treatment and long-term morbidity.
The ultimate decision whether or not to offer the patient venous thromboprophylaxis remains the prerogative of the surgeon, whose decision should be based on a case-by-case basis, determining the risk/benefit ratio for the individual patient. 
